CardioVascular BioTherapeutics Financial Statements
CardioVascular BioTherapeutics Financial Information
| Company Type | Public Single Location |
|---|---|
| Fiscal Year-End | December |
| Annual Report | Company Web Site |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
CardioVascular BioTherapeutics Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.0 | 0.0 | 0.0 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (20.7) | (18.9) | (11.1) |
| Total Net Income ($ mil.) | (36.0) | (5.6) | (12.4) |
| Diluted EPS (Net Income) | (0.27) | (0.04) | (0.10) |
CardioVascular BioTherapeutics Stock Quote & Chart
10/13/08 13:47:40 EST •
NASDAQ OTC BB •
0.22
•
 -0.0200
•
-8.3333 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
CardioVascular BioTherapeutics Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | -- | 3.44 | 1.55 |
| Price/Earnings Ratio | -- | 15.50 | 15.75 |
| Price/Book Ratio | -- | 2.92 | 1.50 |
| Price/Cash Flow Ratio | -- | 12.78 | 9.64 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed CardioVascular BioTherapeutics Financial Ratios
CardioVascular BioTherapeutics Competitive Intelligence
| Advanced Cell Technology | Cardium Therapeutics | Genzyme | |
|---|---|---|---|
| Annual Sales ($ mil.) | 0.6 | 1.6 | 3,813.5 |
| Employees | -- | -- | 10,000 |
| Market Cap ($ mil.) | -- | 90.5 | 21,035.5 |
Competitive Landscape
